Compound Summary
Compound Information
Tamoxifen citrate
Compound Name: | Tamoxifen citrate |
Compound CID: | 2733525 |
Synonyms: | Tamoxifen citrate 54965-24-1 Istubal Tamoxifen (Citrate) Tamoxifen citrate salt More... |
Iupac Name: | 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid |
InChI: | InChI=1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-; |
InChIKey: | FQZYTYWMLGAPFJ-OQKDUQJOSA-N |
Canonical Smiles: | CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O |
Isomeric Smiles: | CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O |
Molecular Weight: | 563.6 |
Molecular Formula: | C32H37NO8 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
Tamoxifen citrate
Molecular Weight: | 563.6 |
Molecular Formula: | C32H37NO8 |
Hydrogen Bond Donor Count: | 4 |
Hydrogen Bond Acceptor Count: | 9 |
Rotatable Bond Count: | 13 |
Heavy Atom Count: | 41 |
Complexity: | 690 |
Synonyms
Tamoxifen citrate
| Tamoxifen citrate | Tamoxifen citrate |
|---|---|
Tamoxifen citrate |
54965-24-1 |
Istubal |
Tamoxifen (Citrate) |
Tamoxifen citrate salt |
ICI 46474 |
UNII-7FRV7310N6 |
C32H37NO8 |
ICI 46474 citrate |
ICI 46,474 |
Tamoxifen Citrate (Nolvadex) |
54965-24-1 (citrate) |
7FRV7310N6 |
MFCD00058321 |
NSC180973 |
NCGC00024928-06 |
CAS-54965-24-1 |
DSSTox_CID_1301 |
DSSTox_RID_76068 |
DSSTox_GSID_21301 |
Ethanamine, 2-4-(1,2-diphenyl-1-butenyl)phenoxy-N,N-dimethyl-, (Z)-,2-hydroxy-1,2,3-propanetricarboxylate (1:1) |
Zitazonium |
Caditam |
Farmifeno |
Ginarsan |
Jenoxifen |
Ledertam |
Nourytan |
Noxitem |
Oncotam |
Tafoxen |
Tamofen |
Tamoplex |
Tamoxasta |
Terimon |
Zynoplex |
Emblon |
Genox |
Nolgen |
Noltam |
Tamax |
Taxus |
Zemide |
Tamoxifencitrate |
Tamox-Puren |
(Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate |
2-4-(Z)-1,2-diphenylbut-1-enylphenoxy-N,N-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid |
SMR000677949 |
Z-Tamoxifen citrate |
SR-01000075523 |
CCRIS 6718 |
Nolvadex (TN) |
Soltamox (TN) |
2-{4-(1Z)-1,2-diphenylbut-1-en-1-ylphenoxy}-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate (salt) |
Prestwick_458 |
EINECS 259-415-2 |
Tamoxifen citrate USAN:USP:JAN |
Tamoxifen (Nolvadex) |
Tamoxifen Citrate,(S) |
Tamoxifen, citrate salt |
Lopac-T-9262 |
Tamoxifen Z-isomer citrate |
CHEMBL786 |
SCHEMBL6365 |
MLS001055370 |
MLS002154210 |
ARONIS23853 |
SPECTRUM1500557 |
Nolvadex (TN) (AstraZeneca) |
DTXSID8021301 |
Tamoxifen citrate (JP17/USP) |
HMS500M20 |
Tamoxifen citrate salt, >=99% |
HMS1568M14 |
HMS1921C13 |
HMS2092K17 |
HMS2095M14 |
HMS2232E08 |
HMS3263B08 |
HMS3675P04 |
HMS3712M14 |
I.C.I.46474 CITRATE |
Pharmakon1600-01500557 |
hydroxypropane-1,2,3-tricarboxylate |
Tox21_110938 |
Tox21_202070 |
Tox21_300274 |
Tox21_501203 |
CCG-39629 |
NSC757345 |
s1238 |
s1972 |
SBB080554 |
AKOS005111126 |
Tox21_110938_1 |
CS-1852 |
KS-5046 |
LP01203 |
NSC-180973 |
NSC-757345 |
NCGC00016206-01 |
NCGC00016206-02 |
NCGC00016206-03 |
NCGC00016206-04 |
NCGC00016206-05 |
NCGC00016206-06 |
NCGC00024928-02 |
NCGC00024928-23 |
NCGC00094450-01 |
NCGC00094450-02 |
NCGC00094450-03 |
NCGC00094450-04 |
NCGC00254000-01 |
NCGC00259619-01 |
NCGC00261888-01 |
HY-13757 |
M936 |
BCP0726000223 |
Tamoxifen Citrate - CAS 54965-24-1 |
AB0006810 |
EU-0101203 |
SW219368-1 |
T2510 |
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy) |
A19582 |
D00966 |
J10303 |
T 9262 |
965T241 |
Q-201776 |
SR-01000075523-1 |
SR-01000075523-3 |
SR-01000075523-5 |
SR-01000075523-6 |
Q27108378 |
SR-01000075523-10 |
(Z)-1-(4-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene Citrate |
Tamoxifen citrate, European Pharmacopoeia (EP) Reference Standard |
(z)-2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethylethanamine,citrate |
(Z)-2-4-(1,2-Diphenyl-1-butenyl)phenoxy-N,N-dimethylethanamine citrate |
Tamoxifen citrate, United States Pharmacopeia (USP) Reference Standard |
(Z)-2- p-(1,2-Diphenyl-1-butenyl)phenoxy- N, N-dimethylethylamine citrate (1:1) |
(Z)-2-4-(1,2-Diphenyl-1-butenyl)phenoxy-N,N-dimethyl-ethanamine cirtrate (1:1) |
Tamoxifen citrate for performance test, European Pharmacopoeia (EP) Reference Standard |
(2-{4-1,2-diphenylbut-1-en-1-ylphenoxy}ethyl)dimethylamine; 2-hydroxypropane-1,2,3-tricarboxylic acid |
(Z)-(2-(4-(1,2-Diphenylbut-1-enyl)phenoxy)ethyl)dimethylammonium dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate |
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate |
{2-4-((1Z)-1,2-diphenylbut-1-enyl)phenoxyethyl}dimethylamine, 2-hydroxypropa ne-1,2,3-tricarboxylic acid |
{2-4-(1,2-Diphenyl-1-buten-1-yl)phenoxyethyl}dimethylamine 2-hydroxy-1,2,3-propanetricarboxylate salt |
Ethanamine, 2-(4-((1Z)-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) |
Ethanamine,2-diphenyl-1-butenyl)phenoxy-N,N-dimethyl-, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) |
Experimental Data
Tamoxifen citrate
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33 | umol/L | -21 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
Tamoxifen citrate
Statistics Data
Tamoxifen citrate
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | -21 | 1 | 1 |
Statistics Data Visualization
Tamoxifen citrate
